Effects of OsteoKing on Osteoporotic Rabbits

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2015 Mar 28

PMID 25815520

Citations 7

Authors

Lifen Dai

Haiying Wu

Shan Yu

Hongbin Zhao

Lanjie Xue

Ming Xu

Zhiqiang Shen

Min Hu

Affiliations

Soon will be listed here.

Abstract

Heng-Gu-Gu-Shang-Yu-He-Ji, also known as OsteoKing, is used as a herbal Traditional Chinese Medicine for the treatment of bone disease, including femoral head necrosis and osteoarthritis. However, whether OsteoKing has anti-osteoporotic properties has remained to be elucidated. The purpose of the present study was therefore to investigate the effects of OsteoKing on ovariectomy-induced osteoporosis in rabbits. Female New Zealand white rabbits were randomly divided into an ovariectomized (OVX) group and a sham-surgery group. The rabbits in the OVX group were subjected to an ovariectomy, while the rabbits in the sham group were subjected to the removal of an area of fat near the two ovaries. Bone mineral density, mechanical properties, serum biochemical parameters and micro-architecture were examined at 150 days post-OVX to characterize the experimental animal model. Once the osteoporotic rabbit model had been established, the rabbits in the OVX group were divided into the following groups: Model group, nilestriol group and 300 and 600 mg/kg OsteoKing groups, containing 16 rabbits in each group. OsteoKing and nilestriol were administered orally. The bone mineral density, mechanical properties, serum biochemical parameters, histology and micro-architecture were examined using dual-energy X-ray absorptiometric analysis, mechanical assessments, enzyme-linked immunosorbent assays, histopathological evaluation and micro-computerized tomography examination following 60 days and 120 days of treatment, respectively. Treatment with OsteoKing led to an elevation in the bone mineral density of the vertebra and serum phosphorus levels, reduced serum concentrations of osteocalcin, procollagen type I N-terminal peptide, tartrate-resistant acid phosphatase 5b and cross-linked N-telopeptide of type I collagen, improved mechanical properties (maximum load, stiffness and energy absorption capacity), and micro-architecture of the lumbar vertebra in the OVX osteoporotic rabbit model following treatment for 120 days. In conclusion, it was demonstrated that OsteoKing is effective in the prevention of estrogen deficiency-associated bone loss and may be a promising drug for the treatment of post-menopausal osteoporosis.

Citing Articles

Mechanism exploration of Osteoking in the treatment of lumbar disc herniation based on network pharmacology and molecular docking.

Luo X, Liu J, Wang X, Chen Q, Lei Y, He Z J Orthop Surg Res. 2024; 19(1):88.

PMID: 38268042 PMC: 10809614. DOI: 10.1186/s13018-024-04570-w.

Osteoking promotes bone formation and bone defect repair through ZBP1-STAT1-PKR-MLKL-mediated necroptosis.

Zhang S, Liu Y, Ma Z, Gao S, Chen L, Zhong H Chin Med. 2024; 19(1):13.

PMID: 38238785 PMC: 10797925. DOI: 10.1186/s13020-024-00883-4.

Osteoking improves OP rat by enhancing HSP90‑β expression.

Sun Y, Chen R, Zhu D, Shen Z, Zhao H, Lee W Int J Mol Med. 2020; 45(5):1543-1553.

PMID: 32323753 PMC: 7138285. DOI: 10.3892/ijmm.2020.4529.

Rabbit as model for osteoporosis research.

Permuy M, Lopez-Pena M, Munoz F, Gonzalez-Cantalapiedra A J Bone Miner Metab. 2019; 37(4):573-583.

PMID: 31087186 DOI: 10.1007/s00774-019-01007-x.

Effect of Osteoking on the osteogenic and adipogenic differentiation potential of rat bone marrow mesenchymal stem cells in vitro.

Yu C, Dai L, Ma Z, Zhao H, Yuan Y, Zhang Y BMC Complement Altern Med. 2019; 19(1):36.

PMID: 30704468 PMC: 6357478. DOI: 10.1186/s12906-019-2435-6.

References

Garnero P, Sornay-Rendu E, CHAPUY M, Delmas P . Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996; 11(3):337-49. DOI: 10.1002/jbmr.5650110307. View

Whitaker M, Guo J, Kehoe T, Benson G . Bisphosphonates for osteoporosis--where do we go from here?. N Engl J Med. 2012; 366(22):2048-51. DOI: 10.1056/NEJMp1202619. View

Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F . The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res. 2000; 15(8):1537-44. DOI: 10.1359/jbmr.2000.15.8.1537. View

Cao T, Shirota T, Yamazaki M, Ohno K, Michi K . Bone mineral density in mandibles of ovariectomized rabbits. Clin Oral Implants Res. 2001; 12(6):604-8. DOI: 10.1034/j.1600-0501.2001.120608.x. View

Zhao H, Hu M, Liang H . [Experimental study on osteoking in promoting gene expression of core binding factor alpha 1 in necrotic femoral head of rabbits]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006; 26(11):1003-6. View

Shirke S, Jadhav S, Jagtap A . Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats. Exp Biol Med (Maywood). 2008; 233(11):1403-10. DOI: 10.3181/0803-RM-93. View

Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y, Jian L . Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop. 2010; 81(3):396-401. PMC: 2876847. DOI: 10.3109/17453674.2010.483986. View

Chen H, Wu M, Kubo K . Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats. J Ethnopharmacol. 2012; 142(1):80-5. DOI: 10.1016/j.jep.2012.04.017. View

Zhao F, Pollintine P, Hole B, Adams M, Dolan P . Vertebral fractures usually affect the cranial endplate because it is thinner and supported by less-dense trabecular bone. Bone. 2008; 44(2):372-9. DOI: 10.1016/j.bone.2008.10.048. View

10.

Eastell R, Colwell A, Hampton L, Reeve J . Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res. 1997; 12(1):59-65. DOI: 10.1359/jbmr.1997.12.1.59. View

11.

Castaneda S, Largo R, Calvo E, Rodriguez-Salvanes F, Marcos M, Diaz-Curiel M . Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. Skeletal Radiol. 2005; 35(1):34-41. DOI: 10.1007/s00256-005-0022-z. View

12.

Lane N, Kelman A . A review of anabolic therapies for osteoporosis. Arthritis Res Ther. 2003; 5(5):214-22. PMC: 193734. DOI: 10.1186/ar797. View

13.

Reginster J, Sarlet N . The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options. Treat Endocrinol. 2006; 5(1):15-23. DOI: 10.2165/00024677-200605010-00003. View

14.

Akhter M, Cullen D, Gong G, Recker R . Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone. 2001; 29(2):121-5. DOI: 10.1016/s8756-3282(01)00486-0. View

15.

Bouxsein M . Determinants of skeletal fragility. Best Pract Res Clin Rheumatol. 2005; 19(6):897-911. DOI: 10.1016/j.berh.2005.07.004. View

16.

Cao D, Zheng Y, Qin L, Han T, Zhang H, Rahman K . Curculigo orchioides, a traditional Chinese medicinal plant, prevents bone loss in ovariectomized rats. Maturitas. 2008; 59(4):373-80. DOI: 10.1016/j.maturitas.2008.03.010. View

17.

Armamento-Villareal R, Napoli N, Panwar V, Novack D . Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006; 355(19):2048-50. DOI: 10.1056/NEJMc062268. View

18.

Turner A . Animal models of osteoporosis--necessity and limitations. Eur Cell Mater. 2003; 1:66-81. DOI: 10.22203/ecm.v001a08. View

19.

Mosekilde L . Assessing bone quality--animal models in preclinical osteoporosis research. Bone. 1995; 17(4 Suppl):343S-352S. DOI: 10.1016/8756-3282(95)00312-2. View

20.

Hu M, Zhao H, Dong X, Luo D, Zhou X . [General and light microscope observation on histological changes of femoral heads between SANFH rabbit animal models and it were intervened by Osteoking]. Zhongguo Zhong Yao Za Zhi. 2011; 35(21):2912-6. View